Although its role as a predictive marker in sarcoma has not been investigated, the durable response of our patient to pembrolizumab and the correlation with other more established predictive markers suggests that FAT1 could serve as a potential marker to predict response to ICIs in sarcoma patients. Here, FAT1 is linked to sarcoma.